Vorolanib

Vorolanib (CM082) is an orally active, potent multikinase VEGFR/PDGFR inhibitor. Vorolanib is a potent ATP-binding cassette (ABC) transporter inhibitor. Vorolanib is an angiogenesis inhibitor and has antitumor activity combined with ZD1839 (HY-50895) [1][2].

Product Specifications

CAS Number

[1013920-15-4]

Product Name Alternative

CM082; X-82

UNSPSC

12352005

Target

PDGFR; VEGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/vorolanib.html

Purity

99.78

Solubility

DMSO : 27 mg/mL (ultrasonic)

Smiles

O=C1/C(C2=CC(F)=CC=C2N1)=C/C(NC(C)=C3C(N[C@@H]4CN(C(N(C)C)=O)CC4)=O)=C3C

Molecular Formula

C23H26FN5O3

Molecular Weight

439.48

References & Citations

[1]Lejia Xu, et al. CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2. Mol Ther Oncolytics. 2019 Dec 27;16:100-110.|[2]Kun Zhang, et al. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of ZD1839 on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo. Thorac Cancer. 2020 Jun;11 (6) :1566-1577.